RAW-LABS
11.2.2021 18:14:10 CET | Business Wire | Press release
RAW Labs , today announced it has completed a USD 5.5M pre-A funding round raising capital from new and existing investors to support the surge in demand for its revolutionary data management solution. The company also announced Lars Farnstrom as its new CEO.
The financing round was led by a group of investors specializing in investments of high growth technology companies and Investiere.ch. The funding will enable RAW Labs to accelerate the acquisition of large enterprise clients and continue investing in the expansion of the capabilities of its core NoDB data platform. Claude Honegger (former global CIO of Credit Suisse) and Pyrros Koussios (former private equity investor and senior executive at international technology companies) are joining the board of directors.
“We are excited that Lars has accepted the CEO role. His long experience in enterprise software from companies like Siebel Systems and C3.ai is a tremendous asset and will enable us to take RAW Labs to the next level,” said Ariel Luedi, one of the founding investors of RAW Labs and former CEO of SAP Hybris. Professor Anastasia Ailamaki, co-founder of RAW Labs, will continue as Chief Scientific Officer with the mission to strengthen the company’s research into groundbreaking data management technologies.
RAW Labs’ NoDB is a platform for data engineers, data scientists, and data analysts to seamlessly access, query, clean, and enhance heterogeneous data sources in near real time and transform them into high-value data products for consumption by analytical tools, ML-models, and enterprise applications.
What makes RAW NoDB unique is its revolutionary query engine, which unlike any other solution in the market uses Category Theory. This gives RAW the unique capability to query large and complex data sources at high performance without the need for any costly and time-consuming ETL/ELT preprocessing or integration with data sources.
“It’s a privilege to have a group of sophisticated investors who have proven experience in helping technology companies scale,” said Lars Farnstrom, CEO of RAW Labs. “Data drives digital transformation. We believe that by eliminating the artificial barrier between operational and analytical data, and by enabling this in record time and without any expensive integrations, RAW Labs can help companies accelerate their digital transformation. Just connect your data sources and start asking questions that will help you unlock new insights on how to reduce costs or increase sales.”
About RAW Labs
RAW Labs, an École Polytechnique Fédérale de Lausanne (EPFL) spinout, helps companies unlock the value of data by providing a single unified platform to effortlessly access and convert any data source into data products for new insights and better decision making, at a fraction of the time and cost of traditional solutions. RAW is available on premise, in the cloud, or in hybrid mode.
For more information, visit https://www.raw-labs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005738/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release
Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release
The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom